Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): A bispecific single chain antibody construct ~~binding molecule~~, whereby said ~~molecule~~ bispecific single chain antibody construct comprises at least two domains,

(a) wherein ~~one~~ a first domain of said at least two domains specifically binds to~~/interacts with~~ the human CD3 complex, wherein said first domain comprises an amino acid sequence of an antibody ~~derived~~ light chain having the amino acid sequence selected from the group consisting of:

(i) the amino acid sequence of SEQ ID NO.: 10; ~~or is~~

(ii) the amino acid sequence encoded by [[a]] the nucleic acid sequence of SEQ ID NO.: 9; and

(iii) the amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to the nucleic acid sequence of (ii); and

(b) wherein a second domain is or contains at least one ~~further antigen-interaction-site~~ antigen-binding-site and/or at least one ~~further~~ effector domain.

2-3. (Canceled)

4. (Currently Amended): The bispecific single chain antibody construct ~~binding molecule~~ according to claim 1, wherein the first domain which binds to~~/interacts with~~ the human CD3 complex is a scFv.

5. (Canceled)

6. (Currently Amended): The bispecific single chain antibody construct ~~binding molecule~~ according to claim 1, wherein the first domain which binds to~~/interacts with~~ the human CD3 complex comprises or consists of the amino acid sequence as depicted in SEQ ID NO.: 14 or encoded by [[a]] the nucleic acid sequence of SEQ ID NO: 13.

7. (Currently Amended): The bispecific single chain antibody construct ~~binding molecule~~ according to claim 1, wherein said antigen-binding-site in said second domain is ~~at least one further antigen-interaction-site~~ specific for one or more cell surface molecule(s).

8. (Currently Amended): The bispecific single chain antibody construct ~~binding molecule~~ according to claim 7, wherein said one or more cell surface molecule(s) is/are a tumor specific molecule(s).

9. (Currently Amended): The bispecific single chain antibody construct ~~binding molecule~~ according to claim 7, wherein said second domain is a ~~further~~ scFv.

10. (Currently Amended): The bispecific single chain antibody construct ~~binding molecule~~ according to claim 7, wherein said second domain specifically binds to~~/interacts with~~ an antigen selected from the group consisting of EpCAM, CCR5, CD19, HER-2, HER-3, HER-4, EGFR, PSMA, CEA, MUC-1 (mucin), MUC2, MUC3, MUC4, MUC5AC, MUC5B, MUC7, bhCG, Lewis-Y, CD20, CD33, CD30, ganglioside GD3, 9-O-Acetyl-GD3, GM2, Globo H, fucosyl GM1, Poly SA, GD2, Carboanhydrase IX (MN/CA IX), CD44v6, Sonic Hedgehog (Shh), Wue-1, Plasma Cell Antigen, (membrane-bound) IgE, Melanoma Chondroitin Sulfate Proteoglycan (MCSP), CCR8, TNF-alpha precursor, STEAP, mesothelin, A33 Antigen, Prostate Stem Cell Antigen (PSCA), Ly-6 desmoglein 4, E-cadherin neoepitope, Fetal Acetylcholine Receptor, CD25, CA19-9 marker, CA-125 marker and Muellerian Inhibitory Substance (MIS) Receptor type II, sTn (sialylated Tn antigen; TAG-72), FAP (fibroblast activation antigen), endosialin, EGFRvIII, L6, SAS, CD63, TF-antigen, Cora antigen, CD7, CD22, Igα, Igβ, gp100, MT-MMPs, F19-antigen and CO-29.

11. (Withdrawn – Currently Amended): The bispecific single chain antibody construct ~~binding molecule~~ according to claim 10, wherein said second domain comprises an amino acid sequence selected from the group consisting of:

(a) an amino acid sequence ~~corresponding to~~ of SEQ ID NO.: 16 or 18;

(b) an amino acid sequence encoded by [[a]] the nucleic acid sequence ~~corresponding to~~ of SEQ ID NO.: 15 or 17; and

(c) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to ~~a nucleotide~~ the nucleic acid sequence ~~of any one~~ of (b).

12. (Withdrawn – Currently Amended): The bispecific single chain antibody construct ~~binding molecule~~ according to claim 11, wherein said single chain antibody construct ~~molecule~~ comprises an amino acid sequence selected from the group consisting of:

(a) an amino acid sequence ~~corresponding to~~ of SEQ ID NO.: 20;

(b) an amino acid sequence encoded by [[a]] the nucleic acid sequence ~~corresponding to~~ of SEQ ID NO.: 21; and

(c) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to ~~a nucleotide~~ the nucleic acid sequence ~~of any one~~ of (b).

13. (Currently Amended): The bispecific single chain antibody construct ~~binding molecule~~ according to claim 10, wherein said second domain comprises an amino acid sequence selected from the group consisting of:

(a) an amino acid sequence ~~corresponding to~~ of SEQ ID NO.: 22, 24, 26, 28, 30[[,]] or 32;

(b) an amino acid sequence encoded by [[a]] the nucleic acid sequence ~~corresponding to~~ of SEQ ID NO.: 21, 23, 25, 27, 29[[,]] or 31; and

(c) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to ~~a nucleotide~~ the nucleic acid sequence of any one of (b) ~~and (c)~~.

14. (Currently Amended): The bispecific single chain antibody construct ~~binding molecule~~ according to claim 13, wherein said bispecific single chain antibody construct ~~molecule~~ comprises an amino acid sequence selected from the group consisting of:

(a) an amino acid sequence ~~corresponding to~~ of SEQ ID NO.: 34[[,]] or 36;

(b) an amino acid sequence encoded by [[a]] the nucleic acid sequence ~~corresponding to~~ of SEQ ID NO.: 33[[,]] or 35; and

(c) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to ~~a nucleotide~~ the nucleic acid sequence of any one of (b).

15. (Currently Amended): The bispecific single chain antibody construct ~~binding molecule~~ according to claim 7, wherein said ~~at least one further antigen interaction site~~ antigen-binding site is humanized.

16. (Withdrawn – Currently Amended): A nucleic acid sequence encoding [[a]] the bispecific single chain antibody construct ~~binding molecule~~ according to claim 1.

17. (Withdrawn - Currently Amended): The nucleic acid sequence ~~molecule~~ of claim 16 comprising a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence encoding the mature form of a protein comprising the amino acid sequence selected from the group of SEQ ID NOs: 20, 34[[,]] and 36;

(b) a nucleotide sequence comprising or consisting of a DNA sequence selected from the group of SEQ ID NOs: 19, 33[[,]] and 35; ~~and~~

(c) a nucleotide sequence encoding a protein having an amino acid sequence at least 95% identical to the amino acid sequence encoded by the nucleotide sequence of (a) or (b); and[[;]]

(d) a nucleotide sequence which is degenerate as a result of the genetic code to a nucleotide sequence of any one of (a) to **(c)**.

18. (Withdrawn – Currently Amended): A vector comprising [[a]] the nucleic acid sequence according to claim 16.

19. (Withdrawn): The vector of claim 18, which further comprises a regulatory sequence operably linked to said nucleic acid sequence.

20. (Withdrawn): The vector of claim 18, wherein the vector is an expression vector.

21. (Withdrawn): A host transformed or transfected with a vector according to claim 18.

22. (Withdrawn – Currently Amended): A process for the production of a bispecific single chain antibody construct ~~binding molecule~~ according to claim 1, said process comprising culturing a host transformed or transfected with a vector comprising a nucleic acid sequence encoding the bispecific single chain antibody construct ~~binding molecule~~ of claim 1 under conditions allowing the expression of the bispecific single chain antibody construct ~~binding molecule~~ and recovering the produced bispecific single chain antibody construct ~~binding molecule~~ from the culture.

23. (Currently Amended): A composition comprising [[a]] the bispecific single chain antibody construct ~~binding molecule~~ according to claim 1, ~~a nucleic acid molecule encoding the bispecific binding molecule of claim 1, a vector comprising a nucleic acid sequence encoding the bispecific binding molecule of claim 1 or a host transformed or transfected with a vector comprising a nucleic acid sequence encoding the bispecific binding molecule of claim 1~~ and, optionally, a proteinaceous compound capable of providing an activation signal for immune effector cells.

24. (Original): The composition of claim 23 which is a pharmaceutical composition further comprising suitable formulations of carrier, stabilizers and/or excipients.

25. (Currently Amended): The composition of claim 23 which is a diagnostic composition ~~further comprising means and methods~~ for detection of proliferative diseases, tumorous diseases, inflammatory diseases, immunological disorders, autoimmune diseases, infectious diseases, viral diseases, allergic reactions, parasitic reactions, graft-versus-host diseases or host-versus-graft diseases.

26. (Canceled)

27. (Withdrawn - Currently Amended): A method for the treatment or amelioration of a proliferative disease, a tumorous disease, an inflammatory disease, an immunological disorder, an autoimmune disease, an infectious disease, viral disease, allergic reactions, parasitic reactions, graft-versus-host diseases or host-versus-graft diseases in a subject in the need thereof, said method comprising the step of administrating an effective amount of the bispecific single chain antibody construct ~~binding molecule~~ according to claim

~~1, a nucleic acid molecule encoding the bispecific binding molecule of claim 1, a vector comprising a nucleic acid sequence encoding the bispecific binding molecule of claim 1 or a host transformed or transfected with a vector comprising a nucleic acid sequence encoding the bispecific binding molecule of claim 1~~.

28. (Withdrawn): The method of claim 27, wherein said subject is a human.

29. (Withdrawn): The method of claim 27 further comprising the administration of a proteinaceous compound capable of providing an activation signal for immune effector cells.

30. (Withdrawn – Currently Amended): The method of claim 27, further comprising the administration of a proteinaceous compound capable of providing an activation signal for immune effector cells, wherein said proteinaceous compound is administered simultaneously or non-simultaneously with said bispecific single chain antibody construct ~~binding molecule , said nucleic acid molecule, said vector, or said host~~.

31. (Currently Amended): A kit comprising the bispecific single chain antibody construct ~~binding molecule~~ according to claim 1~~, a nucleic acid molecule comprising a nucleic acid sequence encoding the bispecific binding molecule of claim 1, a vector comprising a nucleic acid sequence encoding the bispecific binding molecule of claim 1 or a host transformed or transfected with a vector comprising a nucleic acid sequence encoding the bispecific binding molecule of claim 1~~.